These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 9107118)

  • 1. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
    Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
    J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot medroxyprogesterone acetate pioneers. A retrospective study at a North Carolina Health Department.
    Potter LS; Dalberth BT; Cañamar R; Betz M
    Contraception; 1997 Nov; 56(5):305-12. PubMed ID: 9437559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
    Nelson AL
    J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo-Provera.
    Sharts-Hopko NC
    MCN Am J Matern Child Nurs; 1993; 18(2):128. PubMed ID: 8492647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women.
    Cuong DT; My Huong NT
    Contraception; 1996 Sep; 54(3):169-79. PubMed ID: 8899259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New contraceptives in the 1990s.
    O'Connell BJ
    Curr Opin Pediatr; 1995 Aug; 7(4):371-5. PubMed ID: 7581638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression in users of depo-medroxyprogesterone acetate.
    Westhoff C; Wieland D; Tiezzi L
    Contraception; 1995 Jun; 51(6):351-4. PubMed ID: 7554975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contraceptive use of depot medroxyprogesterone acetate.
    Hickey M; Fraser I
    Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh.
    Swenson I; Khan AR; Jahan FA
    Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adolescent satisfaction with postpartum contraception and body weight concerns.
    Hellerstedt WL; Story M
    J Adolesc Health; 1998 Jun; 22(6):446-52. PubMed ID: 9627814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.